Is Cilgavimab + Tixagevimab registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Cilgavimab + Tixagevimab.

Is Cilgavimab + Tixagevimab authorised in the European Union?

EMA lists 0 centrally authorised medicines containing Cilgavimab + Tixagevimab.

Active substances

Cilgavimab + Tixagevimab

SFDA 1
EMA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
EVUSHELD	100,100 mg/ml,mg/ml	Solution for injection · Intramuscular use	2 Vial	SAR 6806.25	Biological · Prescription	AstraZeneca UK Limited	Withdrawn by MAH · Not Marketed

EMA European Union — centrally authorised medicines

Evusheld AstraZeneca AB · Withdrawn · authorised 25 Mar 2022

Therapeutic indication (EMA)

Prevention of COVID-19.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.